Producer
GL Biochem (Shanghai)
One of the world's largest peptide & amino-acid makers; 200+ Fmoc unnatural amino-acid SKUs.
1
Inputs supplied
1
Goods downstream
1
Facilities
0
Stories
What they make
1 input GL Biochem (Shanghai) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something GL Biochem (Shanghai) makes — pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
Protected amino acids (Fmoc / Boc)
Peptide synthesis reagents & resins
Custom & contract peptide synthesis (CRO/CDMO)
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Concentration2024
The "China exposure" in the GLP-1 supply chain is usually framed as the active ingredient. But the dependency runs two layers deeper. Before the semaglutide API exists, someone has to supply the protected amino-acid building blocks and coupling reagents that solid-phase peptide synthesis consumes — including specialized residues like Aib (α-aminoisobutyric acid) that appear in the GLP-1 backbone. That building-block tier is heavily China-concentrated, and GL Biochem (Shanghai) is one of the top two global suppliers. So even a GLP-1 maker that runs its own peptide synthesis outside China can still be dependent on Chinese reagent supply for the raw protected amino acids feeding the reactor — a chokepoint hidden beneath the API chokepoint that most supply-risk models stop at.
GL Biochem (Shanghai) Ltd. ↗Did you know2024
GL Biochem's protected amino acids and peptide-synthesis reagents are not GLP-1-specific — they are the common substrate of the entire peptide-therapeutics pipeline. The same Fmoc building blocks, resins and coupling reagents go into peptide drugs for diabetes, oncology, cardiovascular and rare disease, plus diagnostic and research peptides and cosmeceutical peptides. Because GLP-1 demand now consumes an enormous and growing share of global protected-amino-acid capacity, the obesity-drug boom competes for the same reagent supply that every other peptide drug program depends on — a cross-program squeeze at the reagent tier analogous to the device-capacity squeeze happening at the autoinjector tier.
GL Biochem (Shanghai) Ltd. ↗Origin2024
GL Biochem was founded in Shanghai in 1994, years before peptide drugs were a household idea, to make protected amino acids and reagents for solid-phase peptide synthesis — the bench chemistry of building a peptide one amino acid at a time on a resin bead. For two decades that was a quiet specialty-reagent business serving academic and pharma labs. Then the GLP-1 era arrived: semaglutide and tirzepatide are peptides, and every gram of them is assembled from exactly the kind of Fmoc-protected amino acids GL Biochem had spent 30 years learning to make at scale (its catalog now exceeds 200 unnatural amino-acid SKUs). A reagent house built for research labs became foundational infrastructure for the world's best-selling drug class.
GL Biochem (Shanghai) Ltd. ↗